



*IFW*

Certificate of Mailing (37 C.F.R. §1.8):  
I hereby certify that this correspondence is being deposited with the United States Postal Service as **First Class Mail** in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on this **10th** day of June 2004.  
s/ Rachel Potash  
Rachel Potash

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
**Sacha Ninkovic et al.**

Serial No.: **10/754,171**

Confirmation No.: **8481**

Filed: **January 9, 2004**

For: **TRICYCLIC COMPOUNDS PROTEIN  
KINASE INHIBITORS FOR ENHANCING THE  
EFFICACY OF ANTI-NEOPLASTIC AGENTS  
AND RADIATION THERAPY**

Group Art Unit: **Not Yet Assigned**

Examiner: **Not Yet Assigned**

Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith are the following documents:

1. **Return Receipt Postcard**
2. **Transmittal of IDS**
3. **PTO.SB/08A Form 1449**
4. **Copies of Cited Art**

**1 postcard;  
2 pages;  
9 pages; and  
110 references.**

Respectfully submitted,

\_\_\_\_\_  
Elsa Djuardin, Ph.D.  
Attorney For Applicant  
Registration No. 45,963

Date: June 10, 2004

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 638-6117  
Fax: (858) 678-8233





Certificate of Mailing (37 C.F.R. §1.8):  
I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
**First Class Mail** in an envelope addressed to:  
Commissioner for Patents, PO Box 1450, Alexandria,  
VA 22313-1450, on this 10<sup>th</sup> day of June, 2004.

s/ Rachel Potash  
Rachel Potash

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
**Sacha Ninkovic et al.**

Serial No.: **10/754,171**

Confirmation No.: **8481**

Filed: **January 9, 2004**

For: **TRICYCLIC COMPOUNDS PROTEIN  
KINASE INHIBITORS FOR ENHANCING THE  
EFFICACY OF ANTI-NEOPLASTIC AGENTS  
AND RADIATION THERAPY**

Group Art Unit: **Not Yet Assigned**

Examiner: **Not Yet Assigned**

Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. § 1.97(b) or 1.97(c)**

**37 CFR § 1.97(b)**

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

**37 CFR § 1.97(c)**

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.



- ☒ Applicant requests that the Examiner consider the following copending applications:

Application Serial No.	Filing Date
10/264,018 (reference AE on Form 1449)	October 2, 2002

- ☐ Copies of these copending applications are enclosed.

- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.

- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. [REDACTED]. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.

- ☒ This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).

- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Date: June 10, 2004

Respectfully submitted,



Elsa Djuardi, Ph.D.  
Attorney For Applicant  
Registration No. 45,963

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 638-6117  
Fax: (858) 678-8233



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

**Complete if Known**

Application Number	10/754,171
Filing Date	January 9, 2004
First Named Inventor	Sacha Ninkovic
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25144A

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup>			
	AA	6,211,164	04-03-2001	LUO, Y., et al.	
	AB	6,383,744	05-07-2002	GREEN, S., et al.	
	AC	6,413,755	07-02-2002	LUYTEN, W.H.M.L, et al.	
	AD	6,495,541	12-17-2002	WEBBER, S., et al.	
	AE	20030078254	04-24-2003	WEBBER, S., et al.	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AF	EP 1096014 A2	05-02-2001	CHEN, P., et al.		
	AG	WO 00/16781	03-30-2000	GILMARTIN, A.G., et al.		
	AH	WO 00/42040	07-20-2000	WEBBER, S., et al.		
	AI	WO 01/16306	03-08-2001	INNIS, M.A., et al.		
	AJ	WO 01/16136 A2	03-08-2001	WEBBER, S.E., et al.		
	AK	WO 01/21771	03-29-2001	SUGANUMA, M., et al.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/754,171
Filing Date	January 9, 2004
First Named Inventor	Sacha Ninkovic
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25144A

AL	WO 02/44183 A2	06-06-2002	FERRARIS, D., et al.		
AM	WO 02/070494	09-12-2002	KEEGAN, K.S., et al.		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AN	ACCILI, D., "A Kinase In the Life of The $\beta$ Cell," <i>Journal of Clinical Investigation</i> , 2001, pp. 1575-1576, vol. 108, no. 11.	
	AO	AL-KHODAIRY, F., et al., "Identification And Characterization Of New Elements Involved In Checkpoint And Feedback Controls In Fission Yeast," <i>Molecular Biology of the Cell</i> , 1994, pp. 147-160, vol. 5.	
	AP	BAGSHAW, K., et. al., "Antibody-Directed Enzyme Prodrug Therapy: A Review," <i>Drug Development Research</i> , 1995, pp. 220-230, vol. 34.	
	AQ	BARBER, A., et al., "Insulin Rescues Retinal Neurons From Apoptosis By A Phosphatidylinositol 3-Kinase/Akt-Mediated Mechanism That Reduces The Activation Of Caspase-3," <i>Journal of Biological Chemistry</i> , 2001, pp. 32814-32821, vol. 276, no. 35.	
	AR	BARTEK, J., et al., "CHK2 Kinase – A busy Messenger," <i>Nature Reviews Molecular Cell Biology</i> , 2001, pp. 877-886, vol. 2.	
	AS	BELSCHES, A.P., et al., "Role of C-SRC Tyrosine Kinase in EGF-Induced Mitogenesis," <i>Frontiers in Bioscience</i> , 1997, Electronic Publication 2: D501-D518.	
	AT	BERTOLINI, G., et. al., "A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Lefluonamide, a Potent Immunosuppressive Drug," <i>Journal of Med. Chem.</i> , 1997, 2011-2016, 40.	
	AU	BERVEN, L., et al., "Cellular Function of p70 <sup>S6K</sup> . A Role in Regulation Cell Motility," <i>Immunology and Cell Biology</i> , 2000, pp. 447-451, vol. 78, no. 4.	
	AV	BISHOP, A.L., et al., "Rho GTPases and Their Effector Proteins," <i>Biochem. J.</i> , 2000, pp. 241-255, vol. 348.	
	AW	BJORGE, J., et al., "Selected Glimpses Into The Activation And Function Of Src Kinase," <i>Oncogene</i> , 2000, pp. 5620-5635, vol. 19, no. 49.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/754,171
Filing Date	January 9, 2004
First Named Inventor	Sacha Ninkovic
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25144A

AX	BLUME-JENSEN, P., et al., "Oncogenic Kinase Signalling," <i>Nature</i> , 2001, pp. 355-365, vol. 411, no. 6835.
AY	BODOR, N., "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems," <i>Advances in Drug Research</i> , 1984, pp. 254-331, vol. 13.
AZ	BRANDON, E., et al., "PKA Isoforms, Neural Pathways, And Behaviour: Making The Connection," <i>Current Opinion in Neurobiology</i> 1997, pp. 397-403, vol. 7.
BA	BRAZIL, D., et al., "Ten Years Of Protein Kinase B Signalling: A Hard Akt To Follow," <i>Trends in Biochemical Sciences</i> , 2001, pp. 657-664, vol. 26, no. 11.
BB	BRUSHIA, R.J., et al., "Phosphorylase Kinase: The Complexity of its regulation is Reflected in the Complexity of its Structure," <i>Frontiers in Bioscience</i> (Electronic Publication), 1999, pp. D618-D641, vol. 4.
BC	BUNDGAARD, H., <u>Design and Application of Prodrugs, Chapter 5, Drug Design Application and Development</u> , 1991, Harwood Academic Publishers.
BD	BUNDGAARD, H., et al., <u>Design of Prodrugs</u> , 1985, Elsevier Press.
BE	BUOLAMWINI, J., "Cell Cycle Molecular Targets In Novel Anticancer Drug Discovery," <i>Current Pharmaceutical Design</i> , 2000, pp. 379-392, vol. 6.
BF	CALAUTTI, E., et al., "Fyn Tyrosine Kinase Is A Downstream Mediator Of Rho/PRK2 Function In Keratinocyte Cell-Cell Adhesion," <i>Journal of Cell Biology</i> 2002, pp. 137-148, vol. 156, no. 1.
BG	CANNON, et al., "6-Hydroxy-4-[2-(di-n-Propylamino)ethyl]indole: Synthesis And Dopaminergic Actions," <i>J. Med. Chem.</i> , 1984, pp. 386-389, vol. 27.
BH	CARTER, C., "Protein Kinase C As A Drug Target: Implications For Drug Or Diet Prevention And Treatment Of Cancer," <i>Current Drug Targets</i> 2000, pp. 163-183, vol. 1, no. 2.
BI	CHAMOIN, S., et al., "The Stille Cross Coupling Reactions On Solid Support. Link To Solution Phase Directed Ortho Metalation. An Ester Linker Approach To Styryl, Biaryl And Heterobiaryl Carboxylic Acids," <i>Tetrahedron Letters</i> , 1998, pp. 4175-4178, vol. 39.
BJ	CHEN, Z., et al., "Map Kinases," <i>Chemical Reviews</i> , 2001, pp. 2449-2476, vol. 101, no. 8.
BK	CLERK, A., et al., "Untangling The Web: Specific Signaling From PKC Isoforms To MAPK Cascades," <i>Circulation Research</i> , 2001, pp. 847-849, vol. 89, no. 10.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/754,171
Filing Date	January 9, 2004
First Named Inventor	Sacha Ninkovic
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25144A

BL	COBB, M., et al., "Dimerization In MAP-Kinase Signaling," <i>Trends in Biochemical Sciences</i> , 2000, pp. 7-9, vol. 25, no. 1.
BM	COBB, M., et al., "How MAP Kinases Are Regulated," <i>Journal of Biological Chemistry</i> , 1995, pp. 14843-14846, vol. 270, no. 25.
BN	COE, J., et al., "Convenient Preparation Of N-Substituted Indoles By Modified Leimgruber-Batcho Indole Synthesis," <i>Tetrahedron Letters</i> , 1996, pp. 6045-6048, vol. 37, no. 34.
BO	DAVIS, J.D., "The Mitogen-activated Protein Kinase Signal Transduction Pathway," <i>Journal of Biological Chemistry</i> , pp. 14553-14556, vol. 17, no. 15.
BP	DEAK, M., et al., "Mitogen- and Stress-Activated Protein Kinase-1 (MSK1) is Directly Activated by MAPK And SAPK2/p38, And May Mediate Activation Of CREB," <i>EMBO J.</i> , 1998, pp. 4426-4441, vol. 17, no. 15.
BQ	DEUCHER, A., et al., "Calcium-Dependent Involucrin Expression Is Inversely Regulated By Protein Kinase C (PKC) $\alpha$ And PKC $\delta$ ," <i>Journal of Biological Chemistry</i> , 2002, pp. 17032-17040, vol. 277, no. 19.
BR	ELLIS, L., et al., "Vascular Endothelial Growth Factor In Human Colon Cancer: Biology And Therapeutic Implications," <i>Oncologist</i> , 2000, pp. 11-15, vol. 5 (suppl. 1).
BS	FAGNOLA, M., et al., "Solid-Phase Synthesis Of Indoles Using The Palladium-Catalysed Coupling Of Alkynes With Iodoaniline Derivatives," <i>Tetrahedron Letters</i> , 1997, pp. 2307-2310, vol. 38, no. 13.
BT	FAN, et al., "Cellular Effects of Olomoucine in Human Lymphoma Cells Differing in p53 function," <i>Chemotherapy</i> , 1999, pp. 437-445, vol. 45.
BU	FLAGGS, G., et al., "Atm-dependent interactions of a mammalian Chk1 homolog with meiotic chromosomes," <i>Current Biology</i> , 1997, pp. 977-986, vol. 7.
BV	FRANK, R., "Perspective: Potential New Medical Therapies For Diabetic Retinopathy: Protein Kinase C Inhibitors," <i>American Journal of Ophthalmology</i> , 2002 pp. 693-698, vol. 133, no. 5.
BW	FRIEDMAN, J., "Fat In All The Wrong Places," <i>Nature</i> , 2002, pp. 268-269 vol. 415, no. 17.
BX	FUNDER, J., "Aldosterone Action: New Answers, New Questions," <i>Molecular and Cellular Endocrinology</i> , 1999, pp. 1-3 vol. 151, nos. 1-2.
BY	GARCIA-ECHEVERRIA, C., "Antagonists Of The Src Homology 2 (SH2) Domains Of Grb2, Src, Lck And ZAP-70," <i>Current Medicinal Chemistry</i> , 2001, pp. 1589-1604, vol. 8.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/754,171
Filing Date	January 9, 2004
First Named Inventor	Sacha Ninkovic
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25144A

BZ	GRAVES, D., et al., "Substrate And Inhibitor Recognition Of Protein Kinases: What Is Known About The Catalytic Subunit Of Phosphorylase Kinase," <i>Pharmacol. Ther.</i> , 1999, pp. 143-155, vol. 82, nos. 2-3.
CA	GREENBERG, S., et al., "Role Of PKC And Tyrosine Kinase In Ethanol-Mediated Inhibition Of LPS-Inducible Nitric Oxide Synthase," <i>Alcohol</i> , 1998, pp. 167-175, vol. 16, no. 2.
CB	GREENE, T., et al., <u>Protecting Groups in Organic Synthesis</u> , 2 <sup>nd</sup> ed., John Wiley & Sons, Inc.
CC	GROSS, C., et al., "The Protein Kinase C-Related Kinase PRK2 Interacts With The Protein Tyrosine Phosphatase PTP-BL Via A Novel PDZ Domain Binding Motif," <i>FEBS Letters</i> , 2001, pp. 101-104, vol. 496, nos. 2-3.
CD	HALPERN, M., et al. "Endogenous c-src As A Determinant Of The Tumorigenicity Of src Oncogenes," <i>Proc. Natl. Acad. Sci. USA</i> , 1996, pp. 824-827, vol. 92, no. 2.
CE	HARRISON's, <u>Principles of Internal Medicine</u> , 11 ed, McGraw-Hill Book Company.
CF	HASKELL, M., et al., "C-Src Tyrosine Phosphorylation Of Epidermal Growth Factor Receptor, P190 RhoGAP, And Focal Adhesion Kinase Regulates Diverse Cellular Processes," <i>Chemical Reviews</i> , 2001, pp. 2425-2440, vol. 101.
CG	HIDALGO, M., et al., "The Rapamycin-Sensitive Signal Transduction Pathway As A Target For Cancer Therapy," <i>Oncogene</i> , 2000, pp. 6680-6686, vol. 19, no. 56.
CH	KAMP, T.J., et al., "Regulation of Cardiac L-Type Calcium Channels by Protein Kinase A and Protein Kinase C," <i>Circulation Research</i> , 2000, pp. 1095-1102, vol. 87, no. 12.
CI	KEMP, B., et al., "Dealing With Energy Demand: The AMP-Activated Protein Kinase," <i>Trends in Biochemical Sciences</i> , 1999, 22-25, vol. 24, no. 1.
CJ	KILIMANN, M.W., "Glycogen Storage Disease Due to Phosphorylase Kinase Deficiency," <u>Protein Dysfunction and Human Genetic Disease</u> , 1997, Chapter 4, pp. 57-75.
CK	KUMAR, C.C., et al., "Drugs Targeted Against Protein Kinases," <i>Expert. Opin. Emerging Drugs</i> , pp. 303-315, vol. 6, no. 2.
CL	LAROCK, R., <u>Comprehensive Organic Transformations: A Guide To Functional Group Preparations</u> , 2 <sup>nd</sup> ed., 1989, Wiley-VCH Inc.
CM	LEE, J., et al., "Inhibition Of p38 MAP Kinase As A Therapeutic Strategy," <i>Immunopharmacology</i> 2000, pp. 185-201, vol. 47, nos. 2-3.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/754,171
Filing Date	January 9, 2004
First Named Inventor	Sacha Ninkovic
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25144A

CN	LESLIE, N., et al., "Phosphoinositide-Regulated Kinases And Phosphoinositide Phosphatases," <i>Chem Rev.</i> 2001 pp. 2365-2380, vol. 101.
CO	LITKE, A., et al., "Versatile Catalysts For The Suzuki Cross-Coupling Of Arylboronic Acids With Aryl And Vinyl Halides And Triflates Under Mild Conditions," <i>J. Am. Chem. Soc.</i> , 2000, pp. 4020-4028, vol. 122.
CP	MAGNELLI, L., et al., "Regulation of p53 Protein Kinase C During Multi-Stage Carcinogenesis," <i>Journal of Cancer Research and Clinical Oncology</i> , 1997, pp. 365-369 vol. 123, no. 7.
CQ	MAJOLINI, M.B., "Dysregulation of the Protein Tyrosine Kinase LCK in Lymphoproliferative Disorders and in Other Neoplasias," <i>Leukemia and Lymphoma</i> , 1999, pp. 245-254 vol. 35, no. 3-4
CR	MEDEMA, R., et al., "AFX-Like Forkhead Transcription Factors Mediate Cell-Cycle Regulation By Ras And PKB Through p27 <sup>kip1</sup> ," <i>Nature</i> , 2000 pp. 782-787 vol. 404.
CS	MENDEL, D.B., "Development of SU5416, A selective Small Molecule Inhibitor of VEGF Receptor Tyrosine Kinase Activity, as an Anti-Angiogenesis Agent," <i>Anti-Cancer Drug Design</i> , 2000, pp. 29-41, vol. 15.
CT	MILLAUER, B., et al., "Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types <i>in Vivo</i> ," <i>Cancer Research</i> , 1996, pp. 1615-1620, vol. 56.
CU	MOHAMMADI, M., et al., "Crystal Structure of an Angiogenesis Inhibitor Bound to the FGF Receptor Tyrosine Kinase Domain," <i>EMBO J.</i> 1998, pp. 5996-5904, vol. 17.
CV	MOHAMMADI, M., et al., "Identification Of Six Novel Autophosphorylation Sites On Fibroblast Growth Factor Receptor 1 And Elucidation Of Their Importance In Receptor Activation And Signal Transduction," <i>Molecular Cellular Biology</i> , 1996, pp. 977-989, vol. 16, no. 3.
CW	MUISE-HELMERICKS, R., et al., "Cyclin D Expression Is Controlled Post-Transcriptionally Via A Phosphatidylinositol 3-Kinase/Akt-Dependent Pathway," <i>Journal of Biological Chemistry</i> , 1998, pp. 29864-29872, vol. 273, no. 45.
CX	NARUMIYA, S., et al., Regulators and Effectors of Small GTPases, Part D, <i>Methods in Enzymology</i> , 2000, pp. 273-284, vol. 325
CY	NESHER, R., et al., "β-Cell Protein Kinases And The Dynamics Of The Insulin Response To Glucose," <i>Diabetes</i> , 2002, pp. S68-S73 vol. 51 (Suppl. 1).
CZ	NEWGARD, C., et al., "Organizing Glucose Disposal: Emerging Roles Of The Glycogen Targeting Subunits Of Protein Phosphates-1," <i>Diabetes</i> , 2000, pp. 1967-1977, vol. 49.
DA	NEWTON, A., "Protein Kinase C: Structural And Spatial Regulation By Phosphorylation, Cofactors, And Macromolecular Interactions," <i>Chem. Rev.</i> , 2001, pp. 2353-2364, vol. 101.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/754,171
Filing Date	January 9, 2004
First Named Inventor	Sacha Ninkovic
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25144A

DB	NICHOLSON, K., et al., "The Protein Kinase B/Akt Signalling Pathway In Human Malignancy," <i>Cellular Signalling</i> , 2002, pp. 381-395, vol. 14, no. 5.
DC	NOMURA, M., et al., "Mitogen- And Stress-Activated Protein Kinase 1 Mediates Activation Of Akt By Ultraviolet B Irradiation," <i>Journal of Biological Chemistry</i> , 2001, pp. 25558-25567, vol. 276, no. 27.
DD	NURSE, P., "Checkpoint Pathways Come Of Age," <i>Cell</i> , 1997, pp. 865-867 vol. 91.
DE	PARAST, C., et al., "Characterization And Kinetic Mechanism Of Catalytic Domain Of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR2 TK), A Key Enzyme In Angiogenesis," <i>Biochemistry</i> , 1998, pp. 16788-16801, vol. 37.
DF	PAREKH, D., et al., "New EMBO Member's Review: Multiple Pathways Control Protein Kinase C Phosphorylation," <i>EMBO J.</i> , 2000, pp. 496-503, vol. 19, no. 4.
DG	PENG, C.Y., et al., "Mitotic And G2 Checkpoint Control: Regulation of 14-3-3 Protein Binding By Phosphorylation Of Cdc25C On Serine-216," <i>Science</i> , 1997, pp. 1501-1505, vol. 277.
DH	PETERSON, R., et al., "Kinase Phosphorylation: Keeping It All In The Family," <i>Current Biology</i> 1999, pp. R521-R524, vol. 9, no. 14.
DI	RESH, M.D., "Fyn, A Src Family Tyrosine Kinase," <i>J of Biochemistry &amp; Cell Biology</i> , pp. 1159-1162, vol. 30, no. 11.
DJ	RHIND, N., et al., "Roles Of The Mitotic Inhibitors Wee1 And Mik1 In The G <sub>2</sub> DNA Damage And Replication Checkpoints," <i>Molecular and Cellular Biology</i> , 2001, pp. 1499-1508, vol. 21, no. 5.
DK	ROOVERS, et al., "Integrating the MAP Kinase Signal into the G1 Phase Cell Cycle Machinery," <i>BioEssays</i> , 2000, pp. 818-826, vol. 22, no. 9.
DL	ROSENZWEIG, T., et al., "Differential Effects Of Tumor Necrosis Factor- $\alpha$ and $\delta$ Mediate Inhibition Of Insulin Receptor Signaling," <i>Diabetes</i> , 2002, pp. 1921-1930, vol. 51, no. 6.
DM	RUDERMAN, N., et al., "Malonyl-CoA, Fuel sensing, and Insulin Resistance," <i>American Journal of Physiology</i> , 1999, pp. E1-E18, vol. 276.
DN	SAKAMOTO, K.M., "Semaxanib SUGEN," <i>Idrugs</i> , 2001, pp. 1061-1067, vol. 4, no. 9.
DO	SANCHEZ, Y., et al., "Conservation Of The Chk1 Checkpoint Pathway In Mammals: Linkage Of DNA Damage To Cdk Regulation Through Cdc25," <i>Science</i> , 1997, pp. 1497-1501, vol. 277, no. 5.
DP	SEBOLT-LEOPOLD, JS. "Development Of Anticancer Drugs Targeting The MAP Kinase Pathway," <i>Oncogene</i> 2000, pp. 6594-6599, vol. 19.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/754,171
Filing Date	January 9, 2004
First Named Inventor	Sacha Ninkovic
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25144A

DQ	SHABB, J., "Physiological Substrates Of camp-Dependent Protein Kinase," <i>Chemical Reviews</i> , 2001, pp. 2381-2411, vol. 101, no. 8.
DR	SHAN, D., et al., "Prodrug Strategies Based On Intramolecular Cyclization Reactions" <i>J. Pharm. Sci.</i> 1997, pages 765-767 vol. 86, no. 7.
DX	SKALHEGG, B.S., et al., "Specificity in the cAMP/PKA Signaling Pathway, Differential Expression, Regulation, and Subcellular Localization of Subunits of PKA," 2000, <i>Frontiers in bioscience Electronic Publication</i> , 5:D678-D693.
DT	SONOGASHIRA, K., et al., "A Convenient Synthesis Of Acetylenes: Catalytic Substitutions Of Acetylenic Hydrogen with Bromoalkenes, Iodoarenes, and Bromopyridines," <i>Tetrahedron Lett.</i> , 1975, pp. 4467-4470, no. 50.
DU	STILL, W., et al., "Rapid Chromatographic Technique For Preparative Separations With Moderate Resolution," <i>Journal of Organic Chemistry</i> , 1978, pp. 2923-2925, Vol. 43, No. 14.
DV	STRAWN, L.M., et al., "Flk-1 as Target for Tumor Growth Inhibition," <i>Cancer Research</i> , 1996, pp. 3540-3545, vol. 56.
DW	STRELKOV, I.S., "Ser-10 Phosphorylation of Histone H3 and Immediate Early Gene Expression in Oncogene-transformed Mouse Fibroblasts," <i>Cancer Research</i> , pp. 75-78, vol. 62, no. 1.
DX	TOKER, A., et al., "Cellular Signaling: Pivoting Around PDK-1," <i>Cell</i> , 2000, pp. 185-188, vol. 103.
DY	TORTORA, G., et al., "Oral Antisense That Targets Protein Kinase A Cooperates With Taxol And Inhibits Tumor Growth, Angiogenesis, And Growth Factor Production," <i>Clinical Cancer Research</i> , 2000 pp. 2506-2512, vol. 6.
DZ	TORTORA, G., et al., "Protein Kinase A Type I: A Target For Cancer Therapy," <i>Clinical Cancer Research</i> 2002, pp. 303-304, vol. 8.
EA	YU, C.F., et al., "ERK regulates the Hepatocyte Growth Factor-mediated Interaction of Gab1 and the Phosphatidylinositol 3-Kinase," <i>Journal of Biological Chemistry</i> , 2001, pp. 32552-32558, vol. 276, no. 35.
EB	VAJKOCZY, P., "Inhibition of Tumor Growth, Angiogenesis, and Microcirculation by the Novel Flk-1 Inhibitor SU5416 as Assessed by Intravital Multi-fluorescence Videomicroscopy," <i>Neoplasia</i> , 1999, pp. 31-41, vol. 1, no. 1.
EC	VÉNIEN-BRYAN, C., et al., "Three-Dimensional Structure Of Phosphorylase Kinase At 22 Å Resolution And Its Complex With Glycogen Phosphorylase b," <i>Structure</i> , 2002, pp. 33-41, vol. 10.
ED	VERREY, F., et al., "Pleiotropic Action of Aldosterone in Epithelia mediated by Transcription and Post-transcription Mechanisms," <i>Kidney International</i> , 2000, pp. 1277-1282, vol. 57, no. 4.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**Complete if Known**

Application Number	10/754,171
Filing Date	January 9, 2004
First Named Inventor	Sacha Ninkovic
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	PC25144A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



EE	WALWORTH, N., "Fission yeast <i>chk1</i> protein kinase links the <i>rad</i> checkpoint pathway to <i>cdc2</i> ," <i>Nature</i> , 1993, pp. 368-371, vol. 363.
EF	WEBB, C.P., et al., "The Geldanamycins are Potent Inhibitors of the Hepatocyte Growth Factor/Scatter Factor-Met-Urokinase Plasminogen Activator-Plasmin Proteolytic Network," <i>Cancer Research</i> , 2000, pp. 342-349, vol. 60, no. 2.
EG	WEINERT, T., "Enhanced: A DNA Damage Checkpoint Meets The Cell Cycle Engine," <i>Science</i> , 1997, pp. 1450-1451, vol. 277.
EH	WICK, et al., "A New Molecular Target of Insulin Action: Regulating the Pivotal PDK1," <i>Current Drug Targets: Immune, Endocrine and Metabolic Disorders</i> , pp. 209-221, vol. 1, no. 3.
EI	YOSHIJI, et al., "Vascular Endothelial Growth Factor Is Essential for Initial but not Continued <i>in Vivo</i> Growth of Human Breast Carcinoma Cells," <i>Cancer Research</i> , 1997, pp. 3924-3928, vol. 57.
EJ	ZHAN, X., et al., "Nonreceptor Tyrosine Phosphatases In Cellular Signaling: Regulation Of Mitogen-Activated Protein Kinases," <i>Chemical Reviews</i> , 2001, pp. 2477-2496, vol. 101.
EK	ZHANG, X., et al., "Trans-1-[(2-Phenylcyclopropyl)methyl]-4-Arylpiperazines: Mixed Dopamine D <sub>2</sub> /D <sub>4</sub> Receptor Antagonists As Potential Antipsychotic Agents," <i>J. Med. Chem.</i> , 2000 pp. 3923-3932, vol. 43
EL	ZHONG, "Ultraviolet B-Induced Phosphorylation Of Histone H3 At Serine 28 Is Mediated By MSK1," <i>Journal of Biological Chemistry</i> , 2001, pp. 33213-33219, vol. 276, no. 35.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.